Pancreatic cancer is the fifth most common cause of cancer mortality in the United States (American Cancer Society, 1987). The vast majority are considered to be ductal in origin. Currently there is no adequate animal model for pancreatic duct cell adenocarcinoma. The overall aim of their proposal will be go develop a transgenic animal model for this neoplasm. We will identify enhancer sequences that modulated pancreatic duct cell specific gene expression, link them to the sequence for SV40 T- antigen, and utilize them to make a transgenic animal model. The CA II gene will be utilized for identification of the duct cell specific enhancer sequences since immunohistochemical evidence suggests that CA II is expressed in human duct cells, but not in acinar or islet cells. CA II was selected because it corresponds to the only duct cell specific gene that has been cloned. In order to identify sequences important in the regulation of CA II gene expression in pancreatic due cells, we will prepare a series of constructs composed of deletion mutants of the human and mouse CA II gene linked to the chloramphenicol acetyl transferase (CAT) gene which will be utilized as a reported sequence. These constructs will be introduced into pancreatic cell lines known to produce CA II. The effects of these different sequences on expression will be determined. The constructs which enhance expression of CAT will be introduced into mice, and those animals expressing CAT will be analyzed for tissue specific expression. When duct cell specific enhancer sequences are identified in the CA II gene region, we will develop a duct cell tumor modern by introducing the constructs containing the enhancer sequences linked to the SV40 T-antigen sequence into mice, to generate transgenic animals. A lack of progress in the understanding of pancreas cancer is in part due to the limited number of pancreatic tumor specimens available for biological research. The development of an adequate animal model is even more important when one considers these limitations.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA049667-02
Application #
3193893
Study Section
Pathology B Study Section (PTHB)
Project Start
1989-05-01
Project End
1992-04-30
Budget Start
1990-05-01
Budget End
1991-04-30
Support Year
2
Fiscal Year
1990
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
Other Domestic Higher Education
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030
Frazier, M L; Fernandez, E; de Llorens, R et al. (1996) Pancreatic adenocarcinoma cell line, MDAPanc-28, with features of both acinar and ductal cells. Int J Pancreatol 19:31-8
Githens, S; Schexnayder, J A; Moses, R L et al. (1994) Mouse pancreatic acinar/ductular tissue gives rise to epithelial cultures that are morphologically, biochemically, and functionally indistinguishable from interlobular duct cell cultures. In Vitro Cell Dev Biol Anim 30A:622-35
Ender, B; Lynch, P; Kim, Y H et al. (1993) Overexpression of an elongation factor-1 gamma-hybridizing RNA in colorectal adenomas. Mol Carcinog 7:18-20
Frazier, M L; Brown, N; Pathak, S et al. (1992) Human cell line from an adenocarcinoma of the ampulla of Vater. In Vitro Cell Dev Biol 28A:149-53
Chi, K; Jones, D V; Frazier, M L (1992) Expression of an elongation factor 1 gamma-related sequence in adenocarcinomas of the colon. Gastroenterology 103:98-102
Githens, S; Schexnayder, J A; Frazier, M L (1992) Carbonic anhydrase II gene expression in mouse pancreatic duct cells. Pancreas 7:556-61
Lew, Y; Jones, D V; Mars, W M et al. (1992) Expression of elongation factor-1 gamma-related sequence in human pancreatic cancer. Pancreas 7:144-52